Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
Status:
Recruiting
Trial end date:
2030-05-31
Target enrollment:
Participant gender:
Summary
This phase I trial tests the safety, side effects, and best dose of E-SYNC chimeric antigen
receptor (CAR) T cells after lymphodepleting chemotherapy in treating patients with EGFRvIII
positive (+) glioblastoma. Chimeric antigen receptor (CAR) T-cell therapy is a type of
treatment in which a patient's T cells (a type of immune system cell) are changed in the
laboratory so the CAR T cells will attack cancer cells. T cells are taken from a patient's
blood. Then the gene for a special receptor that binds to a certain protein on the patient's
cancer cells is added to the T cells in the laboratory. The special receptor is called a
chimeric antigen receptor. Large numbers of the CAR T cells are grown in the laboratory and
given to the patient by infusion for treatment of certain cancers. Lymphodepleting
chemotherapy with cyclophosphamide and fludarabine before treatment with CAR T cells may make
the CAR T cells more effective.
Phase:
Phase 1
Details
Lead Sponsor:
Hideho Okada, MD, PhD
Collaborators:
California Institute for Regenerative Medicine (CIRM) National Cancer Institute (NCI)